Molecular Diagnosis of Lung Cancer

1. Centers for Disease Control and Prevention. Compressed mortality file 1999-2011 [CD- ROM]. Atlanta: National Center for Health Statistics; 2014.Search in Google Scholar

2. National Oncological Hospital, Bulgarian National Cancer Resistry. Cancer Incidence in Bulgaria. Sofia: Paradigma; 2014, 170 p.Search in Google Scholar

3. Chilingirova N, Balabanski L, Toncheva D, Kurteva G, Damyanov D, Chilingirov P. Identifying the genetic landscape of squamous cell carcinoma (SCC) and adenosquamous carcinoma (ASC) of the lung using next- generation sequencing (NGS). Ann Oncol. 2015;26 Suppl: i1- i5.10.1093/annonc/mdv043.16Search in Google Scholar

4. Chilingirova N, Balabanski L, Kurteva G, Toncheva D, Damyanov D, Chilingirov P. Detection of driver mutation heterogeneity in patients with non-small cell lung cancer (NSCLC) using next generation sequencing (NGS). EJC. 2015;51 Suppl 3:S612-S613.10.1016/S0959-8049(16)31692-6Search in Google Scholar

5. Chilingirova N, Balabanski L, Ivanov S, Vazharova R, Toncheva D, Kurteva G. Detection of extensive driver mutation heterogeneity in 5 Bulgarian patients with adenosquamous carcinoma of the lung. Eur J Hum Genet. 2015;23(1).Search in Google Scholar

6. Chilingirova N. [Non-small cell lung cancer in the era of precision medicine]. INSPIRO. 2017;2(40):13-7. Bulgarian.Search in Google Scholar

7. Chilingirova N. [Role of tumor markers]. Rheumatology. 2013;21(1). Bulgarian.Search in Google Scholar

8. Chilingirova N, Kurteva G, Toncheva D. [Lung Cancer and genetics]. Oncology. 2015; 4:40. Bulgarian.Search in Google Scholar

9. Chilingirova N. [Lung Cancer - an overview]. Zdraven Navigator. 2017;3:2-4. Bulgarian.Search in Google Scholar

10. Rousseau B, Jacquot, C, Le Palabe J, Malleter M, Tomasoni C, Boutard T, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment. Sci Rep. 2015 May 26;5:10356.10.1038/srep10356Search in Google Scholar

11. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459- 65.10.1038/nrc1097Search in Google Scholar

12. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C et al. Clinical, pathologic and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16):4532-40.10.1158/1078-0432.CCR-13-0657Search in Google Scholar

13. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small- cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574-9.10.1200/JCO.2011.35.9638Search in Google Scholar

14. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-4.10.1038/nrc1609Search in Google Scholar

15. Popovska S, Chilingirova N, Dineva T, Kamburova Z. Prevalence of epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) in Bulgarian population, J Thorac Oncol. 2016;11(4);Suppl:S128-S129.10.1016/S1556-0864(16)30273-8Search in Google Scholar

16. Lampaki S, Lazaridis G, Zarogoulidis K, Kioumis I, Papaiwannou A, Tsirgogianni K, et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. J Cancer. 2015;6(6):568-74.10.7150/jca.11893443994326000049Search in Google Scholar

17. Vanderbilt-Ingram Cancer Center. Molecular Profiling of Lung Cancer [Internet]. Nashville; c2016. [cited 2018 Febr 18]. Available from: https://www.mycancergenome.org/content/disease/lung-cancer/.Search in Google Scholar

18. Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390-401.10.1016/j.apsb.2015.07.001462944226579470Search in Google Scholar

19. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240-7.10.1158/1078-0432.CCR-12-2246363027023470965Search in Google Scholar

20. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel– Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med. 2006;355(24):2542-50.10.1056/NEJMoa06188417167137Search in Google Scholar

21. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804-9.10.1093/annonc/mdq020292499220150572Search in Google Scholar

22. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227-34.10.1200/JCO.2007.14.546619188680Search in Google Scholar

23. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253-63.10.1634/theoncologist.2008-023219221167Search in Google Scholar

24. Chilingirova N, Hammoudeh Z, Balabanski L, Ivanov S, Vazharova R, Nikolova D, et al. TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer. memo-Magazine of European Medical Oncology. 2016; 9(1):30-8.10.1007/s12254-015-0244-2Search in Google Scholar

25. Chilingirova N, Kurteva G, Toncheva D. TruSight Cancer Sequencing Panel for detecting of driver mutation heterogeneity and pharmacogenetic variants associated with sensitivity to chemotherapy in patients with non-small cell lung cancer (NSCLC). Proceedings of the 8th National Conference for Rare Diseases and Orphan Drugs & 12th Balkan Congress of Human Genetics; 2017 Sept 8-10; Plovdiv, Bulgaria: Abstract book, p.67.Search in Google Scholar

26. Chilingirova N, Hammoudeh Z, Balabanski L, Ivanov S, Vazharova R, Nesheva D, et al. Pharmacogenomic study of non-small cell lung cancer. Eur J Hum Genet. 2015;23(1).Search in Google Scholar

27. Chilingirova N, Chilingirov N. [Pharmacogenetics and drug resistance in oncology]. Rheumatology. 2017 Dec: 35. Bulgarian.Search in Google Scholar

28. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin- treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797-3.10.1158/1078-0432.CCR-07-136418347182Search in Google Scholar

29. Chilingirova N, Chilingirov N. [Therapy related side effects in the treatment of lung cancer]. Rheumatology. 2017 Dec; 1:47. Bulgarian.Search in Google Scholar

30. Chilingirova N. [Mucositis]. In: [Kurteva G, Trifonova I, editors. Treatment related side effects]. Sofia; 2017. p. 149-163. Bulgarian.Search in Google Scholar

31. Hrstka R, Coates PJ, VoJtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med. 2009;13(3):440-53.10.1111/j.1582-4934.2008.00634.x382250719379143Search in Google Scholar

32. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357- 65.10.1038/ng109312567188Search in Google Scholar

33. Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6(11):1793-800.10.1097/JTO.0b013e318227227321841506Search in Google Scholar